Biotech – the red-hot, high risk investment story

Biotech - the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.

The best way to play the biotech boom

Syncona is an unusual investment trust that invests in promising privately held biotech companies. It should be a core holding in any portfolio, says David Stevenson.

How stem cells are changing the face of medicine

We have only just started getting to grips with the vast life-saving potential of stem cells, the basic building blocks of the body. Dr Mike Tubbs explores recent breakthroughs and assesses the state of the market.

How to profit from the age of bespoke medicine

Doctors have traditionally approached diseases with a one-size-fits-all model. But advances in genetics and artificial intelligence are making medical treatment far more personal and effective. Matthew Partridge explains how to profit from this medical revolution.

The drugs don’t work: stopping the spread of the superbugs

Antibiotic resistance could turn medical inconveniences into death sentences and become a bigger killer than cancer. Governments and pharmaceutical companies are fighting back. Sarah Moore reports.

Immunotherapy: new hope in the battle against cancer

Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors can benefit too.

Invest in helium, biotech, and UK small caps in 2019

We asked our contributors to choose their favourite investment ideas from around the world for this year and beyond. Here’s what they came up with.

Investing in healthcare innovation

The Worldwide Healthcare Trust provides investors with access to exciting opportunities, says Max King.

Where to find the pick of the bunch in biotech stocks

Professional investor Ailsa Craig picks three biotech stocks generating revenues and profits, and which have long-term patent protection.

A memorable day for Biogen investors

Biotech company Biogen’s promising treatment for the most common cause of dementia has just cleared a key hurdle.

Three biotech stocks to buy now

Professional investor Daniel Koller picks three cutting edge three biotech stocks to buy now.

Showing page 1 of 10